This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
genetics: Archive
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
biotechs etfs genetics
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
etfs genetics
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
cancer genetics genomics medical
Moving Average Crossover Alert: Passage Bio (PASG)
by Zacks Equity Research
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
genetics medical
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
biofuels cancer genetics genomics medical
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
biotechs coronavirus genetics genomics
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
cloud-computing e-commerce etfs genetics internet
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 20%+ to over $310 million on COVID-19 testing and its mutations
coronavirus genetics genomics medical
The Innovative Future Of ETFs
by Daniel Laboe
Ark Invest is driving a new generation of actively managed ETFs
biotechs etfs genetics software tech-stocks
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
by Sweta Jaiswal, FRM
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
etfs genetics